JAZZ - Jazz Pharmaceuticals' 2025 Vision Seems Optimistic
- Jazz Pharmaceuticals laid out its 2025 vision at the J.P. Morgan Healthcare Conference last month.
- The company expects to generate $5 billion in revenues in 2025 and a five percentage points operating margin improvement.
- The margin goal seems achievable but there are risks on the revenue side given the uncertainty around the company's oxybate franchise.
- $5 billion in 2025 would be the very high end of my estimate range, but I can see the company creating shareholder value even if it falls short of its goal.
For further details see:
Jazz Pharmaceuticals' 2025 Vision Seems Optimistic